AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe -- do little ...